What Medochemie Ltd does

Medochemie Ltd is a privately held, Cyprus-based generic and super-generic pharmaceutical manufacturer founded in 1976 by Dr. Andreas Pittas. The company produces branded generics, super-generics with proprietary delivery technology, and OTC products spanning 10 therapeutic categories (anti-infectives, CNS, cardiovascular, analgesics, respiratory, dermatological, gastrointestinal and others), with a portfolio of approximately 630 products, 500 product combinations, and 5,145 marketing authorisations globally. Core technology includes EU cGMP- and WHO GMP-compliant oral solids, sterile injectables (cephalosporins, penicillins, ampoules), topical liquids and semi-solids, and patented dry powder inhaler (DPI) devices for respiratory care produced at the Andi-Ventis facility. Manufacturing spans 15 sites across Cyprus (9), the Netherlands (FAL Duiven BV) and Vietnam (Medochemie Far East Ltd, 5 sites), with combined annual capacity measured in billions of tablets and hundreds of millions of capsules, vials and ampoules.

Medochemie monetises through three primary channels: (1) branded generic distribution in 122 countries via 19 wholly-owned sales offices and a network of exclusive and non-exclusive agents, with regional sales offices across Europe, MENA, Africa and Southeast Asia; (2) contract manufacturing (CMO) and technology transfer for partners, including the largest multinational generic companies, using EU GMP-certified facilities; and (3) product dossier out-licensing to pharmaceutical companies for registration in 29 countries, supplemented by direct supply into government and relief-organisation tenders such as the WHO mass drug administration program. Pricing is set via government tender bidding, healthcare-system negotiations and competitive market dynamics, with no public price list.

The customer base is institutionally anchored: national healthcare systems, the EU Critical Medicines Alliance, multinational generic licensing partners, and supranational procurement programs. Recent strategic emphasis is on sole-source EU supply of WHO Essential Medicines (notably Praziquantel 600mg), expansion of Vietnamese injectable capacity, and ESG positioning through the EU-funded LIFE Pharma-Detox waste-treatment project and 100% renewable-energy operations at Cyprus factories as of October 2025.

Name

Medochemie Ltd

Legal name

Medochemie Limited

Website

https://medochemie.com

Company type

Private

Founded year

1976

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Medochemie is a Cyprus-headquartered, privately held generic and super-generic pharmaceutical manufacturer founded in 1976, operating 15 EU GMP-certified plants across Cyprus, the Netherlands and Vietnam. It supplies branded generics, super-generics, DPIs, and OTC products across 122 countries through 19 offices, an agent network, contract manufacturing, and dossier licensing for governments and multinational partners.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Sterile Injectable Generics (HLAIABAC), Generic Hospital & Institutional Products (HLAIABAL), Generic Tender & Government Supply Markets (HLAIABAM)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Contract manufacturing
• Respiratory inhalers
• Essential medicines

Headquarters

HQ city

Limassol

HQ country

Cyprus

HQ region

Europe

Offices18 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Branded Generic Pharmaceutical Sales: Sale and distribution of licensed branded generic pharmaceutical products across 122 countries through own offices and agent network. Products cover 10 therapeutic categories including anti-infectives, CNS, and cardiovascular medications.
2. Contract Manufacturing: Contract manufacturing services for partners including technology transfer of production formulation and analytical methods, regulatory support, and EU GMP approved facilities in Vietnam for oral dosage forms, gels, creams, ointments, syrups, and injectable cephalosporins.
3. Product Dossier Licensing: Out-licensing of product dossiers to pharmaceutical companies for market registration, establishing strategic partnerships. Products registered on behalf of customers in 29 countries. Customers include largest multinational generic companies.
4. Government and Institutional Tenders: Supply of pharmaceutical products through government tenders and relief organization procurement, including WHO mass drug administration programs and Critical Medicines supply.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Core offering

Medochemie manufactures and globally distributes branded generic and super-generic pharmaceutical products across 10 therapeutic categories, including anti-infectives, CNS, cardiovascular, and respiratory medicines. The company also provides EU GMP-certified contract manufacturing, technology transfer, regulatory support, and product dossier licensing services to multinational and local pharmaceutical partners through 19 offices, agent networks, and 15 production sites in Cyprus, the Netherlands, and Vietnam.

Product overview

Medochemie is a pharmaceutical manufacturer producing branded generic medicines, super-generics (high-barrier-to-entry generic products with innovative delivery methods), and proprietary medical devices. The company operates three manufacturing hubs in Cyprus, Netherlands, and Vietnam with 15 production facilities. Their portfolio includes 630 pharmaceutical products across 10 therapeutic categories (CNS drugs, anti-infectives, analgesics, cardiovascular, endocrine, antidiabetics, respiratory/anti-allergic, dermatological, gastrointestinal, and miscellaneous), with approximately 5,145 marketing authorisations and 500 product combinations. Core products include branded generics, dry powder inhalers (Brovix, Budeform, Formoterol MC), OTC products (Delmar nasal sprays), and antibiotics (Medoclav, Medaxone, Medovir). Medochemie's supergenerics differentiate through advanced formulations and delivery systems.

Differentiator

Problem solved

Functional benefit

Brands

• Andi-Ventis: Dedicated respiratory products facility producing Dry Powder Inhalers (DPIs) for asthma treatment.

Products and services

• Branded Generic Pharmaceuticals Generic medicines containing the same active ingredient as originator drugs, offered at more affordable prices. The portfolio spans 10 therapeutic categories including anti-infectives, CNS, cardiovascular, analgesics, endocrine, antidiabetics, respiratory/anti-allergic, dermatological, and gastrointestinal. Distributed to hospitals, pharmacies, doctors, and patients across 122 countries through proprietary offices and agent networks.
• Dry Powder Inhalers (DPIs) Super-generic respiratory products including Broxivan (Budesonide + Formoterol), Budeform, and Formoterol MC, manufactured at the Andi-Ventis dedicated respiratory facility using proprietary inhaler device technology. Designed for asthma treatment with innovative delivery methods.
• Praziquantel 600mg Tablets (Bermoxel) Anthelmintic agent tablets for treatment of trematode infections including schistosomiasis, listed on the WHO Essential Medicines List 2025. Medochemie is the only EU supplier with Marketing Authorisation for this product.
• Medoclav / Moxiclav (Amoxicillin/Clavulanic Acid) Broad-spectrum penicillin antibiotic combined with beta-lactamase inhibitor, available as tablets, powder for oral suspension, and injectable forms. Distributed globally as part of Medochemie's anti-infective portfolio.
• Over-the-Counter (OTC) Products Non-prescription pharmaceutical products including the Delmar range of nasal sprays (isotonic and hypertonic sea water solutions in variants with Eucalyptus, Panthenol, and Aloe Vera). Sold through retail pharmacies and consumer health channels.
• Contract Manufacturing (CMO) Services EU GMP-certified contract manufacturing for pharmaceutical partners, including technology transfer of production formulation and analytical methods, regulatory support, and production at facilities in Cyprus, Vietnam, and the Netherlands. Capabilities include oral dosage forms, gels, creams, ointments, syrups, injectable cephalosporins, penicillins, and dry powder inhalers.
• Product Dossier Licensing and Out-Licensing Out-licensing of product dossiers to pharmaceutical companies for market registration and sale in target markets. Products registered on behalf of customers in 29 countries across Western Europe, Canada, Australia, New Zealand, and South Africa. Customers include the largest multinational generic companies.

Quantifiable outcome

• 28% of Cyprus total industrial exports
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• EU Member State Healthcare AuthoritiescoreOthers · 18 June 2026Medochemie is the only EU supplier with Marketing Authorisation for Praziquantel 600mg tablets. First shipment dispatched to Greece with additional shipments planned for other EU member states pending import permits.
• Cyprus Olympic CommitteeminorGTM or Marketing Partner · 1 April 2026Sponsorship agreement supporting Cypriot athletes and promoting Olympic values on the road to Los Angeles 2028. Agreement coincides with Medochemie's 50th anniversary and underscores commitment to health, society, and sport.
• Aarhus UniversitycoreStrategic or Co-development PartnerCollaborating partner in the LIFE Pharma-Detox European project developing an innovative pharmaceutical waste treatment system using advanced oxidation techniques. The four-year EU-funded project involves five partners from four countries.
• NEVIScoreStrategic or Co-development PartnerCollaborating partner in the LIFE Pharma-Detox European project developing an innovative pharmaceutical waste treatment system. The four-year EU-funded project involves five partners from four countries.
• National Technical University of AthenscoreStrategic or Co-development PartnerCollaborating partner in the LIFE Pharma-Detox European project developing an innovative pharmaceutical waste treatment system. The four-year EU-funded project involves five partners from four countries.
• University of CataniacoreStrategic or Co-development PartnerHosted a partners' meeting to evaluate technical progress and define next milestones for the LIFE Pharma-Detox project. One of five partners from four countries in this EU-funded four-year project developing advanced oxidation pharmaceutical waste treatment technology.
• Medicines for EuropecoreStrategic or Co-development PartnerMedochemie is a founding member of Medicines for Europe (formerly European Generics Medicines Association, EGA), representing the European generic, biosimilar, and value-added pharmaceutical industries. Committed to the Code of Conduct for transparent interactions with Healthcare Professionals.
• Critical Medicines AlliancecoreStrategic or Co-development PartnerMedochemie is a member of the Critical Medicines Alliance and holds an extensive portfolio of EU shortlisted critical medicines produced at European authorised facilities. Many of these critical medicines play a key role in the fight against antimicrobial resistance.

Scale indicators19 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer, headquartered in Israel. Directly comparable in terms of broad generic portfolio across multiple therapeutic categories, global distribution network, and branded generic strategy, but operates at substantially larger scale and with biosimilars exposure.
• Sandoz: Novartis's generics and biosimilars division, spun off in 2023. Comparable as a global generics manufacturer with EU GMP manufacturing footprint and broad therapeutic coverage, though Sandoz has stronger biosimilars exposure and Western European manufacturing concentration.
• Viatris: Global pharmaceutical company formed from Mylan-Upjohn combination, offering generic, branded, and biosimilar medicines worldwide. Comparable in global reach and broad therapeutic portfolio, though much larger scale and post-merger integration in progress.
• Sun Pharmaceutical Industries: India's largest pharmaceutical manufacturer and global generic producer. Comparable in generic portfolio breadth, finished dosage form manufacturing, and global export reach, though India-based manufacturing cost structure differs from Medochemie's Cyprus-Vietnam footprint.
• Aurobindo Pharma: Indian-headquartered generic pharmaceutical manufacturer with extensive global footprint including Europe and emerging markets. Comparable in branded generic strategy, formulation manufacturing scale, and antibiotic portfolio emphasis.
• Cipla: Indian generic pharmaceutical major with strong presence in respiratory (including DPI products), anti-infectives, and emerging markets. Comparable in respiratory super-generic ambitions and African/Middle Eastern distribution, though materially larger in scale.

Direct peers

• Krka: Slovenian generic pharmaceutical manufacturer with comparable European-focused generics business, similar therapeutic category coverage, and EU GMP-certified manufacturing. Most directly comparable peer given similar geographic focus, scale, and branded-generic positioning across Central and Eastern Europe.
• Stada Arzneimittel: German-headquartered European generics and consumer healthcare company with comparable product portfolio across multiple therapeutic areas. Similar model of branded generics distributed through European channels with strong presence in Central and Eastern European markets.
• Glenmark Pharmaceuticals: Indian-headquartered generic and specialty pharmaceutical manufacturer with comparable branded generic distribution model across emerging markets, including significant respiratory and dermatology product exposure. Similar therapeutic category breadth and emerging market focus.

Emerging players

• Alvotech: Iceland-based biosimilars developer and manufacturer. Adjacent comparison as a European-headquartered pharmaceutical manufacturer competing in regulated markets, but focuses on biosimilars rather than small-molecule generics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/medochemieltd
• LinkedInlinkedin.com/company/medochemie-ltd

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries20 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medochemie Ltd